3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
9
Peutz-Jeghers Syndrome
3
Exocrine Pancreatic Insufficiency
2
Pancreatic Intraductal Neoplasms
1
Hereditary pancreatitis
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Dysplastic Nevus Syndrome
1
Diabetes Mellitus
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Breast Neoplasms
1
Interventions
Cetuximab
5
Irinotecan
3
Gemcitabine
2
tivozanib
1
neratinib
1
lorlatinib
1
liposomal doxorubicin
1
encorafenib
1
binimetinib
1
Taxes
1
Secretin
1
Paclitaxel
1
PX-866
1
Oxaliplatin
1
Lomustine
1
Leucovorin
1
Fluorouracil
1
Doxorubicin
1
Carboplatin
1
Capecitabine
1
CB-839
1
CA-19-9 Antigen
1
Bevacizumab
1
Aspirin
1
Albumin-Bound Paclitaxel
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Secretin
×
Gastrointestinal
×
Clear all
NCT02000089
2025-10-09
CAPS5
Johns Hopkins University
Phase 3
Recruiting
9,000 enrolled